Tavaborole
Based on 2 publication(s) in Google Scholar
Tavaborole (AN-2690) is an antifungal agent with activity against Trichophyton species, in a topical solution formulation for the potential treatment of onychomycosis.
For research use only. We do not sell to patients.
- Purity: 99.74%
- CAS No.: 174671-46-6
- Formula: C7H6BFO2
- Molecular Weight:151.93
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antifungal Compound Library
HY-L048
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Targeted Diversity Library
HY-L099
-
Pediatric Drug Library
HY-L104
-
Off-patent Drug Library
HY-L141
-
F-Fragments Library
HY-L152
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Drug Fragment Library
HY-L904
-
Covalent Fragment Library
HY-L909
-
Serine/Threonine Focused Covalent Fragment Library
HY-L914
-
Multifunctional Covalent Fragment Library
HY-L916
Publications Citing Use of MedChemExpress (MCE) Tavaborole
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
65 μM
Compound: tb
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 31264855] |
| HeLa | CC50 |
>50 μM
Compound: Tavaborole
|
Cytotoxicity against human HeLa cells expressing luciferase-based DENV-2 protease reporter system assessed as reduction in cell viability by celltiter-blue assay
Cytotoxicity against human HeLa cells expressing luciferase-based DENV-2 protease reporter system assessed as reduction in cell viability by celltiter-blue assay
|
[PMID: 35863275] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: tb
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 31264855] |
| SK-OV-3 | IC50 |
>100 μM
Compound: tb
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
|
[PMID: 31264855] |
| WI-38 | IC50 |
32 μM
Compound: tb
|
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
|
[PMID: 31264855] |
Tavaborole (AN-2690) shows an 8-fold increase in activity against C. neoformans, and an 8-fold increase in activity against A. fumigatus[1]. Tavaborole (AN-2690) obviously inhibit the cells expressing GlLeuRS-D444A, but has no effect on the cells expressing GlLeuRS and GlLeuRS-D444E[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 174671-46-6
-
Appearance Solid
-
Molecular Weight 151.93
-
Formula C7H6BFO2
-
Color White to off-white
-
SMILES
OB1OCC2=CC(F)=CC=C21
-
Synonyms
AN-2690
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Bioorg Chem
Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption. [Abstract]2025 Jun 1:159:108421. PMID: 40179579 -
AMB Express
Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening. [Abstract]2022 Dec 1;12(1):151. PMID: 36454354
Solvent & Solubility
DMSO : 100 mg/mL (658.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Baker SJ, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006 Jul 27;49(15):4447-50. [Content Brief]
[2]. Zhou XL, et al. Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690. Biochem J. 2010 Sep 1;430(2):325-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.5820 mL | 32.9099 mL | 65.8198 mL | 164.5495 mL |
| 5 mM | 1.3164 mL | 6.5820 mL | 13.1640 mL | 32.9099 mL | |
| 10 mM | 0.6582 mL | 3.2910 mL | 6.5820 mL | 16.4549 mL | |
| 15 mM | 0.4388 mL | 2.1940 mL | 4.3880 mL | 10.9700 mL | |
| 20 mM | 0.3291 mL | 1.6455 mL | 3.2910 mL | 8.2275 mL | |
| 25 mM | 0.2633 mL | 1.3164 mL | 2.6328 mL | 6.5820 mL | |
| 30 mM | 0.2194 mL | 1.0970 mL | 2.1940 mL | 5.4850 mL | |
| 40 mM | 0.1645 mL | 0.8227 mL | 1.6455 mL | 4.1137 mL | |
| 50 mM | 0.1316 mL | 0.6582 mL | 1.3164 mL | 3.2910 mL | |
| 60 mM | 0.1097 mL | 0.5485 mL | 1.0970 mL | 2.7425 mL | |
| 80 mM | 0.0823 mL | 0.4114 mL | 0.8227 mL | 2.0569 mL | |
| 100 mM | 0.0658 mL | 0.3291 mL | 0.6582 mL | 1.6455 mL |
Powered by Bioz